The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
About the Author
Discover more from InfoVera USA
Subscribe to get the latest posts sent to your email.
